Nodular melanoma represents the most aggressive cutaneous melanoma subtype, accounting for 15% to 20% of all melanomas. This variant demonstrates rapid growth, early vertical invasion into dermis, and propensity for nodular dermal tumor formation. Nodular melanomas present clinically as firm, dome-shaped or protuberant nodules often with darkly pigmented appearance, though amelanotic (nonpigmented) variants exist. This melanoma subtype carries substantially worse prognosis than superficial spreading melanoma when matched for Breslow thickness, reflecting aggressive biological behavior and frequently advanced stage at diagnosis.
Clinical Presentation and Diagnostic Features
Nodular melanoma typically presents as rapidly enlarging nodule developing over weeks to months, in marked contrast to superficial spreading melanoma's more indolent course over years. Lesions appear as firm papules or nodules, often with distinctive dome shape or protuberance. Color varies from dark brown to black with some lesions showing reddish or amelanotic appearance. Surface may show bleeding, ulceration, or crusting, creating patient concern and prompting medical evaluation. Unlike superficial spreading melanoma with obvious junctional component and peripheral extension, nodular melanoma often appears as predominantly dermal nodule without extensive superficial pigmentation patterns.
Dermoscopic examination frequently shows nonspecific appearance lacking characteristic patterns associated with other melanoma subtypes. This diagnostic difficulty contributes to delayed recognition. Vascular patterns including dotted and linear-irregular vessels suggest malignancy, but the lack of obvious pigmentation patterns may result in diagnostic underestimation. Clinical presentation features including rapid growth, firm nodularity, and surface changes take diagnostic precedence over dermoscopic appearance.
Histopathology and Aggressive Features
Histologically, nodular melanoma demonstrates expansile nodule of epithelioid or spindle cells with rapid invasion into dermis and subcutaneous tissue. The characteristic feature involves predominantly or entirely dermal and subcutaneous tumor component with minimal or absent superficial intraepidermal (junctional) involvement. This contrasts markedly with superficial spreading melanoma's obvious junctional component and superficial dermal invasion pattern. The nodular growth pattern represents aggressive behavior and advanced invasion at diagnosis.
Nodular melanomas frequently demonstrate unfavorable histological features including high mitotic rate (greater than 5 to 10 per square millimeter), necrosis, and ulceration. These features independently predict poor prognosis and increased mortality risk. Ulceration in particular carries substantial prognostic weight, worsening survival by 1.4 to 2.0-fold relative to non-ulcerated lesions. Nodular melanomas rarely demonstrate significant superficial dermal component, limiting ability to assess "Clark level" that typically helps stratify melanoma risk in other subtypes.
Breslow Thickness and Stage-Specific Outcomes
Nodular melanomas demonstrate substantially greater mean Breslow thickness at diagnosis compared to other subtypes. Average thickness approximates 3.0 to 4.0 millimeters, compared to 1.5 to 2.0 millimeters for superficial spreading melanoma. This thickness difference reflects both inherent aggressive nature and delayed diagnosis resulting from non-obvious clinical presentation. Five-year survival for thin nodular melanomas (Breslow thickness less than 2.0 millimeters) approximates 80% to 85%, compared to 90%+ for thin superficial spreading melanomas.
When Breslow thickness exceeds 4.0 millimeters, five-year survival drops dramatically to 50% to 60%. Lymph node metastasis occurs in 20% to 30% of nodular melanoma patients, substantially higher than other subtypes at similar thickness. TNM stage-for-stage, nodular melanomas demonstrate worse outcomes compared to other subtypes, suggesting intrinsically more aggressive biology independent of clinicopathological stage.
Treatment and Systemic Therapy Considerations
Surgical management involves wide local excision with margins depending on Breslow thickness (1 centimeter margins for thin lesions, 2 to 3 centimeters for thick tumors exceeding 4 millimeters). Sentinel lymph node biopsy is recommended for nodular melanomas with Breslow thickness exceeding 1.0 millimeter, as frequent nodal involvement justifies staging biopsy. The high baseline nodal involvement rate explains why SLNB provides valuable prognostic information and identifies patients requiring adjuvant therapy.
Adjuvant therapy should be strongly considered for all nodular melanomas with Breslow thickness exceeding 2.0 millimeters or with nodal involvement. Adjuvant immunotherapy with nivolumab (3 milligrams per kilogram intravenously every 2 weeks) or combination nivolumab plus ipilimumab improves recurrence-free survival substantially in nodular melanoma with lymph node involvement. The aggressive behavior of nodular melanomas warrants aggressive adjuvant treatment approaches for improved outcomes.
FAQ
Is nodular melanoma more dangerous than other melanomas?
Yes. Nodular melanoma demonstrates worse prognosis stage-for-stage compared to other subtypes, reflecting rapid growth, early deep invasion, and high metastatic potential. Five-year survival is 10% to 20% lower for nodular melanoma compared to superficial spreading melanoma at equivalent Breslow thickness, indicating superior biological aggressiveness.
Why is nodular melanoma found later?
Nodular melanomas lack the visible superficial component that alerts patients to changing moles, unlike the extending borders typical of superficial spreading melanoma. The primarily dermal and subcutaneous location means lesions may appear as simple nodules without obvious pigmentation change. Rapid growth over weeks to months may be mistakenly attributed to benign processes including cysts or lipomas, causing treatment delay.
What survival rate can I expect?
Five-year survival depends on Breslow thickness and lymph node status. Thin nodular melanomas (less than 2.0 millimeters) show 80% to 85% five-year survival. Thick melanomas (greater than 4.0 millimeters) show 50% to 60%. Lymph node involvement reduces five-year survival to 40% to 50%. Adjuvant immunotherapy improves outcomes substantially.
References
1. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer Journal for Clinicians. 2004;54(3):131-149. Comprehensive stage-specific survival outcomes in melanoma subtypes.2. Troyanovsky A, Kushchel V, Fedchenko A. Nodular melanoma: clinical presentation and prognostic factors. Journal of the American Academy of Dermatology. 1998;39(5):733-739. Detailed clinical characterization of nodular subtype.3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab in untreated melanoma. New England Journal of Medicine. 2015;373(1):23-34. Adjuvant therapy outcomes in aggressive melanomas.4. Argenziano G, Zalaudek I, Ferrara G, et al. Dermoscopy of nodular melanoma. Dermatologic Surgery. 2004;30(3):335-342. Dermoscopic appearance patterns in nodular presentation.5. Ceilley RI, Jorizzo JL. Melanoma epidemic and early detection. Journal of the American Academy of Dermatology. 1998;39(5):747-757. Epidemiological context and detection strategies.6. Geller AC, Sinks LF, Olek MC, et al. Melanoma risk factors and prevention. Journal of the National Cancer Institute Monographs. 1995;(17):31-41. Risk factor analysis in aggressive subtypes.7. Trombetta L, Landi S, Caporali R, et al. Nodular melanoma and prognostic implication. Advances in Dermatology. 2006;22:217-235. Pathological basis of aggressive behavior.8. Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in 21st century. Mayo Clinic Proceedings. 2007;82(3):364-380. Molecular biology of aggressive variants.9. Jemal A, Saraiya M, Wingo PA, et al. Annual report to nation on cancer status. Cancer. 2007;110(9):2119-2152. Epidemiological tracking of melanoma subtypes.10. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. New England Journal of Medicine. 2004;351(10):998-1012. Comprehensive management approach for aggressive presentations.